For nearly two decades, reverse payments have been the perennial focus in the pharmaceutical industry and among antitrust professionals. But while courts continue to grapple with the implications of the Supreme Court's decision in FTC v. Actavis, Inc., 570 U.S. 136 (2013), more attention is being brought to pharmaceutical companies' lifecycle management strategies.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.